Cancer Immunotherapy Guidelines

The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.

cig-big.png

These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies.

In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.

icon-resources.png

The Guidelines

Melanoma

Cancer Immunotherapy Guidelines – Melanoma

Published August 27, 2013 in Nature Reviews Clinical Oncology as "The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma."

An update to the Melanoma guidelines is expected to be published in 2017.

Genitourinary Malignancies

Cancer Immunotherapy Guidelines – Kidney

Published November 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."

Cancer Immunotherapy Guidelines – Prostate

Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."

Cancer Immunotherapy Guidelines – Bladder

Coming soon

Hematologic Malignancies

Cancer Immunotherapy Guidelines – Heme

Published December 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."

Lung Cancer

Cancer Immunotherapy Guidelines – Lung

Coming Soon

IM-CatGraphic-v3_Mem.jpg

Our Experts

SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating the consensus statement; therefore, each Cancer Immunotherapy Guidelines Task Force comprises a comprehensive mix of academic physicians and researchers,nurses, patients, and patient advocates invited from a diversity of institutions across the United States.

Each expert Task Force addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and then develops evidence-based recommendations by recording consensus opinions of the Task Force and documenting alternative opinions when they occur.

Cancer Immunotherapy Guidelines Oversight Committee

Chair

  • Madhav Dhodapkar, MDYale University

Vice Chair

  • Ashish Kamat, MD, MBBS, FACSMD Anderson Cancer Center

Committee Members

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Michael Bishop, MD
The University of Chicago
Michael Boyiadzis, MD
University of Pittsburgh
Julie Brahmer, MD
Johns Hopkins University
Madhav Dhodapkar, MD
Yale University
James Gulley, MD, PhD, FACP
National Cancer Institute
Ramaswamy Govindan, MD
Washington University School of Medicine
Roy Herbst, MD, PhD
Yale Cancer Center
F. Stephen Hodi, MD
Dana-Farber Cancer Institute; Co-Chair
Ashish Kamat, MD, MBBS, FACS
MD Anderson Cancer Center
Howard L. Kaufman, MD, FACS
Rutgers Cancer Institute of New Jersey
John M. Kirkwood, MD
University of Pittsburgh
Douglas G. McNeel, MD, PhD
University of Wisconsin
Brian I. Rini, MD
Cleveland Clinic Taussig Cancer Center
Naiyer Rizvi, MD
Columbia University Medical Center
Jonathan Rosenberg, MD
Memorial Sloan Kettering Cancer Center